Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels
by
Contributor since / Followers
Contributor since / Followers
1 month ago
Rasi Bhadramani/iStock via Getty Images
- Data from a phase 2 trial found that Eli Lilly’s (NYSE:LLY) muvalaplin significntly reduced lipoprotein(a) levels at multiple doses in individuals at high risk of cardiovascular events.
- At the highest dose tested — 240 mg — the reduction was 85.8% compared to placebo at 12 weeks. For other doses tested, the reductions were as follows: 47.6% (10 mg) and 81.7% (60 mg).
- Percent change in Lp(a) from baseline to week 12 was the primary endpoint. Secondary endpoints at all three doses were also met.
- Lilly has another candidate for reducing Lp(a), epodisiran, in phase 3, but it is an injectable medicine. Muvalaplin is given orally.
- The drugmaker said about 20% of people in the U.S. have high levels of Lp(a).